Arctoris To Overhaul Drug Discovery With Automation
Building a robotics infrastructure "is the only way to make sure we generate data of sufficient quality at the speed and scale required, and now everybody in the pharma industry is very excited about the idea of end-to-end automation." So says Martin-Immanuel Bittner, CEO of .
You may also be interested in...
BenevolentAI has added Merck KGaA to its list of partners but the UK firm is looking for a new CEO after Joanna Shields decided to leave as a major restructuring continues.
Following a positive opinion from the CHMP, the Spanish company is hoping to launch its challenger to Dupixent in the EU before the end of the year.
First Wave is licensing Sanofi’s 5-HT4 receptor partial agonist capeserod and is having to pay a mere $500,000 in upfront fees for the privilege.